Gabapentin Tablet, Film Coated
Product Images NDC 71335-1041

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1041). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A text panel showing a formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a sex adjustment factor (0.85 for female patients). The formula is presented clearly in a mathematical expression format.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin showing a cyclohexane ring attached to an aminomethyl group and an acetic acid group.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo and gabapentin at 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows pain scores, with gabapentin demonstrating a decreasing trend in pain scores compared to stable scores for placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over 7 weeks during a 3-week dose titration period followed by a 4-week fixed dose period. It compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day groups, with pain scores decreasing over time in gabapentin groups relative to placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled "Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies" showing results from two studies. The chart compares placebo (PBO) groups with Gabapentin (GBP) groups at different doses, showing higher responder proportions in GBP groups (29% and 32%-34%) compared to placebo (12% and 14%). Statistical significance is indicated for GBP groups relative to placebo.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing difference percentages by daily dose (mg) across three studies labeled a, b, and c. The x-axis represents daily dose in mg (ranging from 600 to 1800), and the y-axis represents difference percentage (ranging from 2 to 22%). Different colored squares represent data points from each study.*

FDA Label Image

Label Image (Lbl713351041)

Gabapentin 800 mg CV tablet label from Bryant Ranch Prepack, packaged in Burbank, CA. The label references comparison to Neurontin 800 mg CV tablet by Strides Pharma Science Limited. It includes instructions to store at 20-25°C (68-77°F) and a warning that it may cause dizziness. The label indicates Rx only and has a quantity of 90 tablets. The NDC number 71335-1041 is shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.